Idrapril, a novel ACE inhibitor

Roberto Latini, Serge Masson, Giuseppina Luvarà, Gordana Jeremic, Fabio Fiordaliso

Research output: Contribution to journalArticlepeer-review


Idrapril, the prototype of a new clinical class of ACE inhibitors, has a pharmacological profile similar to captopril in animals. Preliminary experimental data suggest a lower potential for inducing cough compared to captopril. In humans, it has a short elimination half-life of about 2 h, but a much longer effect on RAS and blood pressure (12 to 24 h), without affecting heart rate.

Original languageEnglish
Pages (from-to)351-363
Number of pages13
JournalCardiovascular Drug Reviews
Issue number4
Publication statusPublished - 1996


  • Angiotensin-converting enzyme inhibitor
  • Antihypertensives
  • Heart
  • Idrapril

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Idrapril, a novel ACE inhibitor'. Together they form a unique fingerprint.

Cite this